ravulizumab aHUS
Selected indexed studies
- Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab. (Kidney Int Rep, 2024) [PMID:39291212]
- Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. (Kidney Int Rep, 2021) [PMID:34169186]
- Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials. (Kidney Med, 2024) [PMID:39105067]
_Worker-drafted node — pending editorial review._
Connections
ravulizumab aHUS is a side effect of
Sources
- Ravulizumab: First Global Approval. (2019) pubmed
- Complement system activation: bridging physiology, pathophysiology, and therapy. (2024) pubmed
- Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab. (2024) pubmed
- Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. (2021) pubmed
- Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials. (2024) pubmed
- The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. (2020) pubmed
- Effectiveness and Safety of Switching to Ravulizumab From Eculizumab in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome: A Global aHUS Registry Analysis. (2025) pubmed
- The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. (2021) pubmed
- Complement inhibitors in pediatric kidney diseases: new therapeutic opportunities. (2024) pubmed
- Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies. (2024) pubmed